INTRODUCTION
Ulcerative Colitis (U.C.) is a chronic idiopathic inflammatory bowel disease (IBD) that differentiates itself by exhibition of a nontransmural, continuous and symmetrical pattern of inflammation limited to the colon with distal to proximal extension in disease progression. U.C. follows a chronic course, punctuated by clinical remissions and relapses [1] .
Typically macroscopic lesions are mucosal ulcerations, with immune cell infiltration and cryptic abscesses at histology. U.C. usually manifests with bloody diarrhea, is associated with a number of extra-intestinal manifestations and may be acutely complicated by toxic megacolon [2] . Diagnosis of U.C. is based on clinical symptoms combined with radiological and endoscopic investigations [3] . Endoscopy remains an invasive, time-consuming, and expensive procedure. Hence, colonoscopy could not be reasonably repeated in the setting of a regular follow-up. Clinical indices are indirect and often inaccurate predictors of endoscopic activity [4] .
The need for a diagnostic tool that would improve the conventional methods in IBD diagnosis directed the search towards potential immunological markers, since an aberrant immune response against microbial or endogenous antigens in a genetically susceptible host seems to be implicated in IBD pathogenesis [5].
Neopterin, a stable pteridine derivative, is synthesised by macrophages upon stimulation with the pro-inflammatory cytokine and Interferon-gamma (IFN-γ) through induced transcriptional activation of the rate-limiting enzyme of pteridines biosynthesis (Oxenkrug et al., 2011). Neopterine is indicative of a proinflammatory immune status. It serves as a marker of cellular immune system activation [6, 7] .
This study aims to evaluate serum neopterin concentration as being a new biomarker for U.C. disease activity evaluation and to correlate it with some of the other markers of disease activity.
SUBJECTS AND METHODS
This case-control study was carried out in Internal and Tropical Medicine departments in collaboration with Clinical Pathology Department, Zagazig University Hospitals in the period from June 2014 to December 2015.
Subjects:
This study included 80 subjects. An informed consent was obtained from all individuals who shared in this study.
Subjects were classified into 2 groups: Control group (group I):
This group included twenty apparently healthy volunteers (13 male representing 65.0 %, 7 female representing 35.0 %, Mean age ± SD 36.0 ± 12.6 y, age Range 19-60 y ). 
Methods
All patients with U.C.were subjected to the following : 1-Full history.
2-Complete physical examination.
3-Abdominal ultrasound: Using GE LogiQ P5 Japan instrument.
4-Calculating the Simple Ulcerative Colitis
Clinical Activity Index Score (SCCAIS) devised by Walmsley et al. [8] ; U.C. was considered active if the (SCCAIS) was ≥5. Significant improvement in U.C disease activity is considered if there is a decrease of >1.5 points in the SCCAI (Table 1) . -Serum neopterin less than 10 nmol/L is considered normal and high if it is more than 10 nmol/L.
Statistical Analysis
All data were entered and analyzed using EpiInfo version 6 and SPSS version 8 for Windows. Mean ± SD Range (nmol/L) There was statistically a high significant difference of serum neopterin among the studied groups (Pvalue <0.001). This study included eighty subjects (twenty apparently healthy volunteers and sixty patients with U.C. [20 patients recently diagnosed as active U.C. disease, 20 patient's clinically in relapse and 20 patients clinically in remission]).
RESULTS
In this study, elevated ESR, decreased (Hb. level & Hct.%) and decreased serum albumin were correlating with disease activity, also there were trends toward an elevated TLC, platelet count, and PT being markers of disease activity. So, these markers may be helpful as indicators for disease activity.
The results of the laboratory tests is in concordance with Sachar and Walfish [12] as they had mentioned that laboratory tests should be done to screen for anemia, hypoalbuminemia, and electrolyte abnormalities in U.C. patients. Liver function tests should be done. Other possible laboratory abnormalities include leukocytosis, thrombocytosis, and elevated acute-phase reactants (eg, ESR).
The number of white blood cells increases during the acute phase response and is also influenced by the drugs utilized in IBD, such as glucocorticoids (increased) or azathioprine and 6-mercaptopurine (decreased). Albumin is a negative acute phase marker and decreased levels may be found during inflammation [13] .
Eng and Surawicz [14] had mentioned that laboratory evaluation may be helpful, but is never diagnostic. For example, an elevated white blood cell count can be seen with either acute self-limiting colitis or IBD. Anaemia, especially iron deficiency anaemia, suggests IBD, as the usual course in acute self-limiting colitis is too short for significant blood loss.
Also, Danese and Fiocchi [15] had mentioned that laboratory measurements are not diagnostic, but are helpful in assessing and monitoring disease activity and in differentiating U.C. from other forms of colitis. Blood counts and measurements of the ESR and the level of fecal lactoferrin or calprotectin help to determine the severity of the inflammation.
Regarding SCCAIS we can found that it is a predictive of U.C. disease activity, but are never diagnostic. This is in concordance with Higgins et al.
[16] as they had mentioned that the SCCAI is the most vigorously validated index in U.C. and has good psychometric and performance validity. The SCCAI is also an adequate replacement for more objective disease activity measurements such as endoscopy and blood tests. The clinician-based SCCAI is able to categorize two types of patients: patients with inactive U.C. disease (SCCAI score <5) and patients with active U.C. disease (SCCAI score ≥5). These assessments require completion by the treating clinician, which makes them prone to bias, since the clinician gives an interpretation of the patient's response.So, this index gives an idea only about U.C. disease activity but not useful to detect the degree of the disease activity [17].
Ciećko-Michalska et al.
[18] have reported that measurement of neopterin concentration in serum may be a useful marker to assess disease activity in patients with IBD. They observed a positive correlation between increased concentrations of neopterin in serum and increased levels of (TNF-α and CRP), increasing the number of (leukocytes and platelets count) and the degree of disease activity in patients with both U.C. and Chron's disease (C.D).
In this study, we found that serum neopterin concentrations for all of the participating control subjects were within the normal value. In comparison to the control group (I), all of the three subgroups of group II U.C. patients interpret higher serum neopterin concentrations, which are above the normal value.
Results in this study found that serum neopterin concentration is greater in patients with active U.C. disease and also increases in pancolitis. As shown in our results serum neopterin level is greater in U.C. patients whose disease affecting the whole colon than those patients with the disease limited to left colon. The previous observation suggests that the serum neopterin level is directly proportional to the extent of the inflammed part of the colon. However, a larger study would be needed to confirm those observations.
Moreover, serum neopterin concentration was significantly greater in patients with clinically active U.C. than in those whose disease was in clinical remission and so; their results are going with the results of Husain et al. [19] .
CONCLUSIONS
 Serum neopterin concentration is increased in patients with clinically active U.C. when compared with controls, and therefore represents a new biomarker for disease activity that could reliably distinguish between clinically active and inactive ulcerative colitis  The degree of elevation in serum neopterin concentration can be used as a helpful tool in predicting the stage of the disease activity. It may be in part related to location and extent of disease.
 Laboratory tests should be done to screen for anemia, hypoalbuminemia, electrolyte abnormalities, and other possible laboratory abnormalities as leukocytosis, thrombocytosis, and elevated acute-phase reactants (eg, ESR). These markers may be helpful as predictors for disease activity and severity, but are never diagnostic.
